Clinical Trial

Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

Study acronym: Baikal
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Prospective open-label randomized parallel groups study to compare efficacy and safety of Indinol Forto® 200 mg capsules and Visanne 2 mg tablets in treatment of endometriosis. This is phase 3 study, based on hypothesis of non-inferiority.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-02.
Trial Details
NCT Number NCT07164183
Lead Sponsor Alcea
Conditions Endometriosis
Enrollment 290 participants
Start Date 2025-09-11
Primary Completion 2026-10 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-18